Zenas BioPharma (ZBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
16 Mar, 2026Voting matters and shareholder proposals
Election of two Class II director nominees, James Boylan and Patrick Enright, to serve until the 2029 Annual Meeting and until successors are elected and qualified.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Provision to transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zenas BioPharma
- Obexelimab cut IgG4-RD flare risk by 56% in Phase 3, meeting all endpoints with strong safety.ZBIO
Study Result9 Jul 2026 - Year-end phase III IgG4-RD results and strong MS data mark key inflection points.ZBIO
Jefferies London Healthcare Conference 20259 Jul 2026 - Obexelimab's clinical programs in IgG4-RD, MS, and lupus advance with key data readouts expected by 2025.ZBIO
Citi's 2024 Global Healthcare Conference8 Jul 2026 - Obexelimab nears launch for IgG4-RD, with a robust neuro pipeline advancing toward key milestones.ZBIO
7th Annual HCW Neuro Perspectives Hybrid Conference15 Jun 2026 - Advancing best-in-class therapies for autoimmune diseases with strong late-stage clinical momentum.ZBIO
Corporate presentation3 Jun 2026 - Obexelimab and orelabrutinib advance toward 2027 launches, targeting multi-billion dollar markets.ZBIO
Corporate presentation13 May 2026 - Q1 2026 net loss rose to $81M; positive Phase 3 data and financing extend runway into 2029.ZBIO
Q1 202613 May 2026 - Directors were elected and the auditor ratified, with final results to be filed in Form 8-K.ZBIO
AGM 202611 May 2026 - 2026 meeting to elect directors, ratify auditor, and highlight governance, compensation, and ESG.ZBIO
Proxy Filing16 Mar 2026